poisar

Stocks · News reference

Cantor Fitzgerald Maintains Overweight on Upexi, Raises Price Target to $2

Benzinga Newsdesk

Cantor Fitzgerald analyst Gareth Gacetta maintains Upexi (NASDAQ:UPXI) with a Overweight and raises the price target from $1.3 to $2.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

UPXI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — UPEXI, INC. (UPXI)

    Filed: 2026-10-13 AccNo: 0001477932-26-006194 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    UPXI
  2. Na

    Upexi to Participate in Upcoming October Investor Conferences

    Upexi, Inc. (NASDAQ: UPXI), a Solana-focused digital asset treasury company, announced that Chief Strategy Officer Brian Rudick will participate in three major investor conferences in October 2026: Maxim Growth Summit, Webull Emerging & Innovative Companies Webinar, and LD Micro 20th Annual Main Event. The company currently holds over 2.34 million SOL and reported digital asset revenue of $17.4 million for fiscal year 2026.

    UPXI
  4. Benzinga Insights

    Full Transcript: Upexi Q4 2026 Earnings Call

    Upexi (NASDAQ:UPXI) released fourth-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and

    UPXI
  6. Benzinga Insights

    Earnings Scheduled For September 17, 2026

    Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10

    IPHAUPXIYI